SavedAdd your journal

Journals / Neurological sciences and neurophysiology (Online) / 2020 / Cilt: 37 - Sayı: 3

The Association of Serum Clusterin Levels and Clusterin rs11136000 Polymorphisms with Alzheimer Disease in a Turkish Cohort

Gamze GÜVEN
Ebru ÖZER
Basar BİLGİÇ
Hasmet HANAGASİ
Hakan GURVİT
Ebba LOHMANN
Nihan ERGİNEL UNALTUNA
Pages
134–140
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Our results showed no significant difference in genotype and allele frequencies of CLU rs11136000 polymorphisms between patients with AD and controls.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Several large‑scale genome association studies have shown that variants in the “Clusterin”’ (CLU) gene are important risk factors for Alzheimer’s disease (AD).
📊
Key Findings & Data:In this study, we aimed to investigate whether the CLU rs11136000 polymorphism was associated with AD in our cohort of Turkish patients.
💡
Conclusion & Impact:Results: Our results showed no significant difference in genotype and allele frequencies of CLU rs11136000 polymorphisms between patients with AD and controls.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: Several large‑scale genome association studies have shown that variants in the “Clusterin”’ (CLU) gene are important risk factors for Alzheimer’s disease (AD). It has also been shown that plasma CLU levels were elevated in patients with AD and associated with disease severity and progression. In this study, we aimed to investigate whether the CLU rs11136000 polymorphism was associated with AD in our cohort of Turkish patients. We also evaluated the association of serum CLU levels and rs11136000 genotypes between patients and controls. Materials and Methods: Genotyping was performed in 327 patients who were diagnosed as having AD (mean age: 67.2 ± 10.8 years) and 344 controls (mean age: 57.7 ± 13.1 years). The rs11136000 genotypes were determined using quantitative real‑time polymerase chain reaction with hydrolysis probes. Serum CLU levels were assessed in 25 patients with AD and 10 controls using enzyme‑linked immunosorbent assay. Results: Our results showed no significant difference in genotype and allele frequencies of CLU rs11136000 polymorphisms between patients with AD and controls. Serum CLU levels in patients with AD did not differ from those of the controls. Furthermore, serum CLU levels showed no major difference between carriers of CC and TT + CT genotypes in the controls and patients with AD. Conclusion: Our results suggest that the CLU rs11136000 polymorphism is not associated with AD in our Turkish patients, and rs11136000 genotypes may not have an effect on serum CLU levels.

🔖

Cite This Article

GÜVEN, G., ÖZER, E., BİLGİÇ, B., HANAGASİ, H., GURVİT, H., LOHMANN, E., UNALTUNA, N. E. (2020). The Association of Serum Clusterin Levels and Clusterin rs11136000 Polymorphisms with Alzheimer Disease in a Turkish Cohort. Neurological sciences and neurophysiology (Online), Cilt: 37 - Sayı: 3, 134–140. https://ajindex.com/articles/290598

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta‑analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet 2007;39:17‑23
  2. De Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: Structure and tissue distribution. Biochemistry 1990;29:5380‑9
  3. Ghiso J, Matsubara E, Koudinov A, Choi‑Miura NH, Tomita M, Wisniewski T, et al. The cerebrospinal‑fluid soluble form of Alzheimer’s amyloid beta is complexed to SP‑40,40 (apolipoprotein J), an inhibitor of the complement membrane‑attack complex. Biochem J 1993;293(Pt 1):27‑30
  4. Golabek A, Marques MA, Lalowski M, Wisniewski T. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 1995;191:79‑82
  5. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer’s amyloid β‑ peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007;27:909‑18
  6. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 2007;21:2312‑22
  7. Nilselid AM, Davidsson P, Nägga K, Andreasen N, Fredman P, Blennow K. Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 2006;48:718‑28
  8. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011;305:1322‑6
  9. Xing YY, Yu JT, Cuic WZ, Zhonga XL, Wua ZC, Zhanga Q, et al. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer’s disease. J Alzheimer Dis 2012;29:515‑9
  10. Mullan GM, McEneny J, Fuchs M, McMaster C, Todd S, McGuinness B, et al. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer’s disease. Curr Alzheimer Res 2013;10:973‑8
  11. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010;67:739‑48
  12. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‑Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzhei